QUOTE AND NEWS
FiercePharma  Mar 27  Comment 
Novo Nordisk will soon resubmit Tresiba to the FDA, earlier than once expected. The escalated timeline provided a substantial boost to Novo's shares, but the news adds pressure to Sanofi's new CEO since Tresiba targets Lantus, the French...
Motley Fool  Mar 25  Comment 
GlaxoSmithKline's share price has stagnated under CEO Andrew Witty. Is it time for a change?
FierceBiotech  Mar 24  Comment 
Thomson Reuters is predicting a big year for blockbuster drugs. Its analysts forecast 11 drugs approved this year will go on to rack up blockbuster sales in 2019, with new treatments from Bristol-Myers Squibb, Sanofi and Novartis leading the pack.
GenEng News  Mar 20  Comment 
Evotec said yesterday it hammered out a definitive agreement for a five-year, minimum-guaranteed €250 million (nearly $270 million) strategic alliance with Sanofi focused on developing multiple products. The announcement confirms a deal the...
FiercePharma  Mar 19  Comment 
Sanofi's Indian affiliate, Shantha Biotechnics, says it's ready to deliver 37 million doses of its low-cost pediatric pentavalent vaccine, Shan5.
FiercePharma  Mar 19  Comment 
Sanofi can go back to the FDA with Lyxumia. The French drugmaker got good news from a cardiovascular outcomes study, required by the FDA before it would approve the diabetes drug.
FierceBiotech  Mar 16  Comment 
While a long list of biopharma companies have been dropping the ax on R&D staffers in recent weeks and months, some of the top execs being shown the exit are finding that new doors are opening as fast as old positions are whisked away. Today, Tal...
FierceBiotech  Mar 12  Comment 
In this week's EuroBiotech Report, Marseille made a pitch to turn its rich history of immunity research into a seat at the top table of immunotherapy R&D. Sanofi and Innate Pharma have signed up as founders of the lab at the center of the push,...
FierceBiotech  Mar 11  Comment 
The French city of Marseille has staked its claim for a corner of the booming immunotherapy R&D ecosystem. And the plan has some big-name backers, with Sanofi and Innate Pharma both signing up as founders of the MI-mAbs immunotherapy research...




 

Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki